Galderma's Guidance Seems Conservative Amid Nemluvio's Success -- Market Talk

Dow Jones

2025/10/06

0802 GMT - Galderma's sales target for this year looks conservative, given the success of its dermatitis drug Nemluvio, Vontobel analyst Stefan Schneider says in a research note. The analyst expects the Swiss skincare company to raise its sales guidance, assuming that sales of Nemluvio were 7% ahead of consensus during the third quarter. "Management has done a great job of positioning Nemluvio in the competitive pharma market," Schneider says. Furthermore, the analyst believes that L'Oreal and Galderma could expand their existing scientific partnership, which would make strong strategic sense. Vontobel upgrades its rating on Galderma to buy from hold. Shares trade 0.2% higher at 140.30 Swiss francs. (andrea.figueras@wsj.com)

(END) Dow Jones Newswires

October 06, 2025 04:02 ET (08:02 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573288627"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573288627\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573288627?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 16:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573288627","market":"sh","top_or_hot":-1,"title":"Galderma's Guidance Seems Conservative Amid Nemluvio's Success -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0802 GMT - Galderma's sales target for this year looks conservative, given the success of its dermatitis drug Nemluvio, Vontobel analyst Stefan Schneider says in a research note. The analyst expects the Swiss skincare company to raise its sales guidance, assuming that sales of Nemluvio were 7% ahead of consensus during the third quarter. \"Management has done a great job of positioning Nemluvio in the competitive pharma market,\" Schneider says. Furthermore, the analyst believes that L'Oreal and Galderma could expand their existing scientific partnership, which would make strong strategic sense. Vontobel upgrades its rating on Galderma to buy from hold. Shares trade 0.2% higher at 140.30 Swiss francs. (andrea.figueras@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 06, 2025 04:02 ET (08:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Galderma's Guidance Seems Conservative Amid Nemluvio's Success -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGalderma's Guidance Seems Conservative Amid Nemluvio's Success -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-06 16:02</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0802 GMT - Galderma's sales target for this year looks conservative, given the success of its dermatitis drug Nemluvio, Vontobel analyst Stefan Schneider says in a research note. The analyst expects the Swiss skincare company to raise its sales guidance, assuming that sales of Nemluvio were 7% ahead of consensus during the third quarter. \"Management has done a great job of positioning Nemluvio in the competitive pharma market,\" Schneider says. Furthermore, the analyst believes that L'Oreal and Galderma could expand their existing scientific partnership, which would make strong strategic sense. Vontobel upgrades its rating on Galderma to buy from hold. Shares trade 0.2% higher at 140.30 Swiss francs. (andrea.figueras@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 06, 2025 04:02 ET (08:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LRLCY","symbol_name":"歐萊雅","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2573288627","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573288627","pubTimestamp":1759737720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0802 GMT - Galderma's sales target for this year looks conservative, given the success of its dermatitis drug Nemluvio, Vontobel analyst Stefan Schneider says in a research note. The analyst expects the Swiss skincare company to raise its sales guidance, assuming that sales of Nemluvio were 7% ahead of consensus during the third quarter. \"Management has done a great job of positioning Nemluvio in the competitive pharma market,\" Schneider says. Furthermore, the analyst believes that L'Oreal and Galderma could expand their existing scientific partnership, which would make strong strategic sense. Vontobel upgrades its rating on Galderma to buy from hold. Shares trade 0.2% higher at 140.30 Swiss francs. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LRLCY":"欧莱雅","BK4183":"个人用品"},"translate_title":"在Nemluvio的成功中，Galderma的指导似乎很保守——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LRLCY":0.9},"content_text":"0802 GMT - Galderma's sales target for this year looks conservative, given the success of its dermatitis drug Nemluvio, Vontobel analyst Stefan Schneider says in a research note. The analyst expects the Swiss skincare company to raise its sales guidance, assuming that sales of Nemluvio were 7% ahead of consensus during the third quarter. \"Management has done a great job of positioning Nemluvio in the competitive pharma market,\" Schneider says. Furthermore, the analyst believes that L'Oreal and Galderma could expand their existing scientific partnership, which would make strong strategic sense. Vontobel upgrades its rating on Galderma to buy from hold. Shares trade 0.2% higher at 140.30 Swiss francs. (andrea.figueras@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 06, 2025 04:02 ET (08:02 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}